【Regional Outlook】Taking China-Originated Therapies Global: Can the Evidence Earn Trust Across Regions?

At a State Council Information Office press conference on July 20, 2026, China’s Ministry of Industry and Information Technology (MIIT) reported that the total value of out-licensing transactions involving Chinese innovative drugs exceeded US$100 billion in the first half of 2026—setting a new record.

But an out-licensing deal is only the starting point. As global partnerships expand beyond single-asset licensing to co-development, platform collaborations, and longer-term value sharing, the critical question is no longer simply:

“Can the asset be licensed?”

It is:

“Can the clinical evidence withstand global regulatory scrutiny?”

Asia-Pacific is not a single clinical trial market. Countries and regions differ in regulatory pathways, clinical practices, patient populations, site capabilities, recruitment dynamics, and communication models. Successful multi-regional clinical trials (MRCTs) require more than adding countries and sites—they require regional differences to be systematically managed from the design stage:

• Strategic planning: Align target markets, regional enrollment allocation, ethnic factors, and endpoint strategies early;

• Site selection: Select sites based on indication-specific fit, investigator experience, enrollment potential, and data quality;

• Data standards: Harmonize laboratory procedures, imaging, endpoint assessments, safety reporting, and data collection requirements;

• Governance & communication: Establish clear cross-regional responsibilities, communication pathways, decision-making processes, and escalation mechanisms.

Evidence with genuine global development value must do more than be generated in China. It must remain interpretable, traceable, and capable of withstanding regulatory review across regions.

Drawing on 23 years of clinical research experience across more than 2,300 projects, including over 200 international multicenter trials, GCP ClinPlus continues to support global development across the Asia-Pacific clinical research ecosystem. Through integrated capabilities spanning medical strategy, regulatory affairs, clinical operations, data management, biostatistics, and quality assurance, we support cross-regional development and the generation of high-quality, globally relevant evidence.

As China-developed therapies accelerate their global development, where do you see the greatest operational challenge today—protocol design, site activation, patient enrollment, data consistency, or cross-regional communication?

We welcome your perspectives. 

#AsiaPacific #ClinicalTrials #MRCT #GlobalClinicalDevelopment #ChinaBiotech #InnovativeTherapies #DataQuality #ClinicalOperations #RegulatoryStrategy #CRO #GCPClinPlus